Match!

Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.

Published on Aug 24, 2019in Inflammatory Bowel Diseases4.005
· DOI :10.1093/ibd/izz164
Freddy Caldera3
Estimated H-index: 3
(UW: University of Wisconsin-Madison),
Luke Hillman2
Estimated H-index: 2
(UW: University of Wisconsin-Madison)
+ 6 AuthorsMary S. Hayney20
Estimated H-index: 20
(UW: University of Wisconsin-Madison)
Abstract
  • References (28)
  • Citations (0)
📖 Papers frequently viewed together
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References28
Newest
#1Jin Gao (CBER: Center for Biologics Evaluation and Research)H-Index: 13
#2Laura Couzens (CBER: Center for Biologics Evaluation and Research)H-Index: 8
Last. Maryna C. Eichelberger (CBER: Center for Biologics Evaluation and Research)H-Index: 20
view all 14 authors...
ABSTRACT The effectiveness of influenza vaccines against circulating A(H1N1)pdm09 viruses was modest for several seasons despite the absence of antigenic drift of hemagglutinin (HA), the primary vaccine component. Since antibodies against HA and neuraminidase (NA) contribute independently to protection against disease, antigenic changes in NA may allow A(H1N1)pdm09 viruses to escape from vaccine-induced immunity. In this study, analysis of the specificities of human NA-specific monoclonal antibo...
3 CitationsSource
#1Andrew Tinsley (Penn State Milton S. Hershey Medical Center)H-Index: 8
#2Seyedehsan Navabi (Penn State Milton S. Hershey Medical Center)H-Index: 2
Last. Kofi Clarke (Penn State Milton S. Hershey Medical Center)H-Index: 4
view all 7 authors...
8 CitationsSource
#1Yoichiro Natori (UHN: University Health Network)H-Index: 6
#2Mika Shiotsuka (UHN: University Health Network)H-Index: 1
Last. Deepali Kumar (UHN: University Health Network)H-Index: 28
view all 12 authors...
23 CitationsSource
#1Shimpei Shirai (Saga University)H-Index: 3
#2Megumi Hara (Saga University)H-Index: 25
Last. Ryuichi Iwakiri (Saga University)H-Index: 34
view all 10 authors...
4 CitationsSource
#1Gary R. Lichtenstein (UPenn: University of Pennsylvania)H-Index: 65
#2Edward Vincent Loftus (Mayo Clinic)H-Index: 83
Last. Bruce E. Sands (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 70
view all 6 authors...
Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of Crohn's disease has steadily increased over the past several decades. The diagnosis and treatment of patients with Crohn's disease has evolved since th
78 CitationsSource
#1Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 129
#2Bruce E. Sands (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 70
Last. Brian G. Feagan (UWO: University of Western Ontario)H-Index: 95
view all 14 authors...
Objective Vedolizumab is a gut-selective antibody to α 4 β 7 integrin for the treatment of ulcerative colitis (UC) and Crohn9s disease (CD). We report an integrated summary of the safety of vedolizumab. Design Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ≥1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-y...
220 CitationsSource
Recent data suggest that inflammatory bowel disease (IBD) patients do not receive preventive services at the same rate as general medical patients. Patients with IBD often consider their gastroenterologist to be the primary provider of care. To improve the care delivered to IBD patients, health main
96 CitationsSource
#1Raj K. KurupatiH-Index: 11
#2Andrew V. KossenkovH-Index: 32
Last. Hildegund C.J. ErtlH-Index: 50
view all 11 authors...
// Raj Kurupati 1,* , Andrew Kossenkov 1,* , Larissa Haut 1 , Senthil Kannan 1,2 , Zhiquan Xiang 1 , Yan Li 1 , Susan Doyle 3 , Qin Liu 1 , Kenneth Schmader 3 , Louise Showe 1 and Hildegund Ertl 1 1 The Wistar Institute, Philadelphia, PA, USA 2 Biomedical Graduate Group, University of Pennsylvania, Philadelphia, PA, USA 3 Development and Division of Geriatrics, GRECC, Durham VA Medical Center and Center for the Study of Aging and Human, Department of Medicine, Duke University Medical Center, Dur...
7 CitationsSource
Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab
6 CitationsSource
#1Jennifer deBruyn (Alberta Children's Hospital)H-Index: 13
#2Kevin FonsecaH-Index: 24
Last. Iwona Wrobel (Alberta Children's Hospital)H-Index: 13
view all 9 authors...
Abstract In patients with inflammatory bowel disease (IBD) on infliximab, data are limited on immune response to influenza vaccine and the impact of vaccine timing. The study aims were to evaluate immune responses to the influenza vaccine in IBD patients on infliximab and the impact of vaccine timing on immune responses. In this randomized study, 137 subjects with IBD on maintenance infliximab therapy were allocated to receive the 2012/2013 inactivated influenza vaccine at the time of infliximab...
21 CitationsSource
Cited By0
Newest
#1Freddy Caldera (UW: University of Wisconsin-Madison)H-Index: 3
#2Dana Ley (UW: University of Wisconsin-Madison)H-Index: 2
Last. Francis A Farraye (Mayo Clinic)H-Index: 4
view all 4 authors...
Recent advances in the treatment of inflammatory bowel disease (IBD) include the use of immune modifiers and monoclonal antibodies, such as tumor necrosis factor (TNF) alpha inhibitors, anti-integrin agents, janus kinase inhibitors, and interleukin-12/23 inhibitors. These agents achieve higher rates of clinical remission and mucosal healing than conventional therapy. However, these therapies increase the risk of infections, including some vaccine-preventable diseases. Infections are one of the m...
Source